In potential $1.2 billion deal, Peninsula biotech sees faster path for Alzheimer's drugs

The South San Francisco biotech traces its roots back to one of the earliest disappointments in Alzheimer's drug development. Now a deal for a heart disease drug could accelerate its Alzheimer's work once again.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news